JP2024534880A - 抗トランスフェリン受容体抗体及びその使用 - Google Patents

抗トランスフェリン受容体抗体及びその使用 Download PDF

Info

Publication number
JP2024534880A
JP2024534880A JP2024513785A JP2024513785A JP2024534880A JP 2024534880 A JP2024534880 A JP 2024534880A JP 2024513785 A JP2024513785 A JP 2024513785A JP 2024513785 A JP2024513785 A JP 2024513785A JP 2024534880 A JP2024534880 A JP 2024534880A
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
antibody
tfr1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024513785A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024534880A5 (enExample
Inventor
アイシン ダルキリッチ－リドル，
ベンジャミン エー． スミス，
カール ジェイ． エム． ハンフ，
ファン チャン，
アール． ブレイク ペピンスキー，
トーマス オー． キャメロン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Biogen MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen MA Inc filed Critical Biogen MA Inc
Publication of JP2024534880A publication Critical patent/JP2024534880A/ja
Publication of JP2024534880A5 publication Critical patent/JP2024534880A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024513785A 2021-09-01 2022-08-31 抗トランスフェリン受容体抗体及びその使用 Pending JP2024534880A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163239630P 2021-09-01 2021-09-01
US63/239,630 2021-09-01
US202263388088P 2022-07-11 2022-07-11
US63/388,088 2022-07-11
PCT/US2022/042196 WO2023034409A1 (en) 2021-09-01 2022-08-31 Anti-transferrin receptor antibodies and uses thereof

Publications (2)

Publication Number Publication Date
JP2024534880A true JP2024534880A (ja) 2024-09-26
JP2024534880A5 JP2024534880A5 (enExample) 2025-08-22

Family

ID=83508506

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024513785A Pending JP2024534880A (ja) 2021-09-01 2022-08-31 抗トランスフェリン受容体抗体及びその使用

Country Status (15)

Country Link
US (2) US11827702B2 (enExample)
EP (1) EP4396231A1 (enExample)
JP (1) JP2024534880A (enExample)
KR (1) KR20240107202A (enExample)
AU (1) AU2022340568A1 (enExample)
CA (1) CA3230796A1 (enExample)
CL (1) CL2024000642A1 (enExample)
CO (1) CO2024003577A2 (enExample)
CR (1) CR20240139A (enExample)
IL (1) IL311175A (enExample)
JO (1) JOP20240042A1 (enExample)
MX (1) MX2024002753A (enExample)
PE (1) PE20240895A1 (enExample)
TW (1) TW202328187A (enExample)
WO (1) WO2023034409A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024187057A2 (en) * 2023-03-08 2024-09-12 Biogen Ma Inc. Anti-transferrin receptor antibodies and uses thereof
AU2024299328A1 (en) 2023-07-21 2026-01-22 Marrow Therapeutics, Inc. Hematopoietic cell targeting conjugates and related methods
CN116735864B (zh) * 2023-08-15 2023-11-10 迦进生物医药(上海)有限公司 评估TfR1抗体血液安全性的试剂盒
TW202517685A (zh) * 2023-10-26 2025-05-01 美商百健Ｍａ公司 抗運鐵蛋白受體抗體及其用途
WO2026076250A1 (en) * 2024-10-03 2026-04-09 Genentech, Inc. Lipid nanoparticles for delivery to the cns from systemic administration

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991004753A1 (en) 1989-10-02 1991-04-18 Cetus Corporation Conjugates of antisense oligonucleotides and therapeutic uses thereof
WO1991014452A1 (en) 1990-03-27 1991-10-03 The Salk Institute For Biological Studies Method for inhibiting cell growth and compositions useful therefor
US5648469A (en) 1992-04-20 1997-07-15 The Salk Institute For Biological Studies Monoclonal antibodies reactive with transferrin receptor cytoplasmic domain
CA2561830C (en) 2004-03-31 2013-05-21 Adnagen Ag Monoclonal antibodies with specificity for fetal erythroid cells
WO2005094364A2 (en) 2004-03-31 2005-10-13 Chimeric Technologies, Inc. Iga antibody protein as a cytotoxic drug
PT1740616E (pt) 2004-04-30 2012-03-23 Inst Nat Sante Rech Med Anticorpo anti-rtf
JP4824025B2 (ja) * 2004-06-07 2011-11-24 マクロジェニックス ウエスト，インコーポレイテッド トランスフェリンレセプター抗体
AU2005287406B2 (en) 2004-07-26 2011-08-18 Biogen Ma Inc. Anti-CD154 antibodies
CA2600929A1 (en) 2005-03-04 2006-09-14 Biogen Idec Ma Inc. Methods of humanizing immunoglobulin variable regions through rational modification of complementarity determining residues
US7736647B2 (en) 2005-06-15 2010-06-15 Monoclonal Antibodies Therapeutics Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells
US20110269665A1 (en) 2009-06-26 2011-11-03 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
FR2953841B1 (fr) 2009-12-16 2011-12-30 Centre Nat Rech Scient Anticorps diriges contre le recepteur de la transferrine et leurs utilisations pour l'immunotherapie des tumeurs qui dependent du fer
FR2959416B1 (fr) 2010-05-03 2012-06-22 Monoclonal Antibodies Therapeutics Mat Biopharma Utilisation d'anticorps anti-cd71 pour la preparation d'un medicament
CA2818173C (en) 2010-11-30 2022-05-03 Genentech, Inc. Low affinity blood brain barrier receptor antibodies and uses therefor
CA2835603A1 (en) 2011-05-09 2012-11-15 Perseus Proteomics Inc. Antibody capable of specifically recognizing transferrin receptor
TWI450727B (zh) 2011-12-29 2014-09-01 財團法人工業技術研究院 抗人類輸鐵蛋白受體的單域抗體與其應用
AU2013203422A1 (en) 2012-01-06 2013-07-18 Bioalliance C.V. Anti-transferrin receptor antibodies and methods using same
HUE045144T2 (hu) 2012-08-29 2019-12-30 Hoffmann La Roche Véragygát-shuttle
CA2893794C (en) 2012-11-08 2021-11-09 University Of Miyazaki Antibody capable of specifically recognizing transferrin receptor
EP2971047A4 (en) 2013-03-15 2016-11-30 Alper Biotech Llc MONOCLONAL ANTIBODIES TO TRANSFERRIN AND TRANSFERRIN RECEPTOR ANTIGEN AND USES THEREOF
EP3594240B1 (en) 2013-05-20 2023-12-06 F. Hoffmann-La Roche AG Anti-transferrin receptor antibodies and methods of use
US9499628B2 (en) 2013-06-14 2016-11-22 Children's Hospital Medical Center Method of boosting the immune response in neonates
EP3088518A4 (en) 2013-12-25 2017-09-20 JCR Pharmaceuticals Co., Ltd. Novel anti-transferrin receptor antibody that passes through blood-brain barrier
CA2932547C (en) 2014-01-06 2023-05-23 F. Hoffmann-La Roche Ag Monovalent blood brain barrier shuttle modules
US10508151B2 (en) * 2014-11-19 2019-12-17 Genentech, Inc. Anti-transferrin receptor antibodies and methods of use
BR112017023862A2 (pt) * 2015-05-04 2018-07-17 Cytomx Therapeutics Inc anticorpos anti-cd71, anticorpos anti-cd71 ativáveis, e métodos de uso destes
EA039366B1 (ru) 2015-06-24 2022-01-19 Джей Си Ар ФАРМАСЬЮТИКАЛЗ КО., ЛТД. Антитело к рецептору трансферрина человека, проникающее через гематоэнцефалический барьер
HUE057952T2 (hu) 2015-06-24 2022-06-28 Hoffmann La Roche Anti-transzferrin receptor antitestek testreszabott affinitással
RU2737637C2 (ru) 2015-07-22 2020-12-01 Инатерис Антитела против tfr и их применение при лечении пролиферативных и воспалительных расстройств
TWI873952B (zh) 2015-10-02 2025-02-21 瑞士商赫孚孟拉羅股份公司 雙特異性抗‐人類cd20/人類轉鐵蛋白受體抗體及使用方法
JP2019513371A (ja) 2016-04-01 2019-05-30 アビディティー バイオサイエンシーズ エルエルシー 核酸ポリペプチド組成物とその使用
DK3473270T5 (da) 2016-06-20 2024-09-09 Genahead Bio Inc Konjugat af antistof-lægemiddel
WO2018081720A1 (en) 2016-10-29 2018-05-03 Rhode Island Hospital Glycosylated transferrin receptor 1 tumor antigen
KR102497564B1 (ko) 2016-12-26 2023-02-07 제이씨알 파마 가부시키가이샤 혈액뇌관문을 통과하는 신규한 항인간 트랜스페린 수용체 항체
CA3053381A1 (en) 2017-02-17 2018-08-23 Denali Therapeutics Inc. Engineered polypeptides
US10457717B2 (en) 2017-02-17 2019-10-29 Denali Therapeutics Inc. Engineered polypeptides
EP3665194A4 (en) 2017-08-10 2021-07-07 Denali Therapeutics Inc. AFFINITY BASED METHODS OF USING TRANSFERRIN RECEPTOR BINDING PROTEINS
AU2018378812B2 (en) 2017-12-06 2025-05-22 Avidity Biosciences, Inc. Compositions and methods of treating muscle atrophy and myotonic dystrophy
IL276327B2 (en) 2018-02-05 2024-05-01 Japan Chem Res Method for delivering drug to muscle
US20210317226A1 (en) 2018-08-02 2021-10-14 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating pompe disease
WO2020028836A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle-targeting complexes and uses thereof in treating muscle atrophy
IL280536B2 (en) 2018-08-02 2024-12-01 Dyne Therapeutics Inc Complexes targeting transferrin receptor and uses thereof
SG11202100928QA (en) 2018-08-02 2021-02-25 Dyne Therapeutics Inc Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
WO2020028842A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating hypertrophic cardiomyopathy
CA3108282A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
KR20210086601A (ko) 2018-08-02 2021-07-08 다인 세라퓨틱스, 인크. 근육 표적화 복합체 및 프리드라이히 운동실조를 치료하기 위한 그의 용도
AU2019314538B2 (en) 2018-08-02 2025-03-13 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
EP3829645A4 (en) 2018-08-02 2022-05-18 Dyne Therapeutics, Inc. MUSCLE TARGETING COMPLEXES AND THEIR USES FOR THE TREATMENT OF PROGRESSIVE FIBRODYSPLASIA OSSIFIANS
EP3830130A4 (en) 2018-08-02 2022-05-18 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating centronuclear myopathy
WO2020104479A1 (en) 2018-11-20 2020-05-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating cancers and resistant cancers with anti transferrin receptor 1 antibodies
US20240148891A1 (en) 2019-10-18 2024-05-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
AU2021206234A1 (en) 2020-01-10 2022-09-01 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
CA3163608A1 (en) 2020-01-10 2021-07-15 Romesh R. Subramanian Muscle-targeting complexes and uses thereof
US20230103793A1 (en) * 2020-01-31 2023-04-06 Dyne Therapeutics, Inc. Anti-transferrin receptor (tfr) antibody and uses thereof
KR20230041760A (ko) 2020-07-23 2023-03-24 다인 세라퓨틱스, 인크. 항-트랜스페린 수용체 (tfr) 항체 및 그의 용도
CA3202832A1 (en) 2020-12-31 2022-07-07 Romesh R. Subramanian Muscle targeting complexes and uses thereof for treating myotonic dystrophy

Also Published As

Publication number Publication date
TW202328187A (zh) 2023-07-16
CR20240139A (es) 2024-06-14
PE20240895A1 (es) 2024-04-24
WO2023034409A1 (en) 2023-03-09
US20230131379A1 (en) 2023-04-27
AU2022340568A1 (en) 2024-03-28
CL2024000642A1 (es) 2024-09-13
CO2024003577A2 (es) 2024-06-27
CA3230796A1 (en) 2023-03-09
KR20240107202A (ko) 2024-07-08
JOP20240042A1 (ar) 2024-02-29
MX2024002753A (es) 2024-05-20
US20240158494A1 (en) 2024-05-16
US11827702B2 (en) 2023-11-28
IL311175A (en) 2024-04-01
EP4396231A1 (en) 2024-07-10

Similar Documents

Publication Publication Date Title
CN111683970B (zh) C-kit结合剂
US11827702B2 (en) Anti-transferrin receptor antibodies and uses thereof
AU2019201141B2 (en) Novel antibody binding to TFPI and composition comprising the same
KR101824512B1 (ko) 과립구-대식세포 콜로니 자극 인자에 대한 항체
CN106459216A (zh) 多特异性抗体构建体
CN118215682A (zh) 抗转铁蛋白受体抗体及其用途
JP7641667B2 (ja) 抗スクレロスチン構築体及びその使用
JP2017513854A (ja) Ｗｉｓｐ１に結合する抗原結合タンパク質
KR20250120344A (ko) 트랜스페린 수용체 결합 단백질
US20220332804A1 (en) Complement C2 Binding Proteins and Uses Thereof
AU2023272924A1 (en) Klrb1 binding agents and methods of use thereof
JP2025503707A (ja) ガレクチン－１０抗体
US12448441B2 (en) ZIP12 antibody
HK40129286A (zh) 抗cd122抗体及其用途
TW202607017A (zh) 抗血清白蛋白之抗原結合蛋白及其用途
WO2026091090A1 (zh) 结合april的抗体及其用途
WO2026017189A2 (zh) 抗il-31抗体、其药物组合物及用途
WO2025207959A1 (en) Anti-transferrin receptor antibodies and uses thereof
CN118139882A (zh) 骨骼肌肉系统疾病的治疗

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250814

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250814